证券代码：603707 证券简称：健友股份 公告编号：2025-060 截至2025年6月30日，尚未转股的"健友转债"金额为人民币502,464,000元，占"健友转债"发行总量的比 例为99.86%。 一、可转债的发行上市概况 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司关于"健友转债"转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 转股情况： ● 未转股可转债情况： 截至2025年6月30日，累计已有人民币719,000元"健友转债"转为公司普通股，累计回售人民币7,000 元"健友转债"。"健友转债"累计转股股数18,035股，占转股前公司股份总额的0.001%。 经中国证券监督管理委员会《关于核准南京健友生化制药股份有限公司公开发行可转换公司债券的批 复》（证监许可[2020]603号）核准，南京健友生化制药股份有限公司（以下简称"公司"）公开发行了 5,031,900张可转换公司债券（以下简称"可转债"或"健友转债"），每张面值人民币1 ...

证券代码：603707 证券简称：健友股份 公告编号：2025-060 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于"健友转债"转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、可转债的发行上市概况 经中国证券监督管理委员会《关于核准南京健友生化制药股份有限公司公开 发行可转换公司债券的批复》（证监许可2020603 号）核准，南京健友生化制 药股份有限公司（以下简称"公司"）公开发行了 5,031,900 张可转换公司债券 （以下简称"可转债"或"健友转债"），每张面值人民币 100 元，发行总额人 民币 5.0319 亿元，期限 6 年。经上海证券交易所自律监管决定书2020134 号 文同意，公司 5.0319 亿元可转债于 2020 年 5 月 22 日起在上海证券交易所挂牌 交易，债券简称"健友转债"，债券代码"113579"。 根据有关规定和《南京健友生化制药股份有限公司公开发行可转换公司债券 募集说明书》的约定，公司该次发行的健友 ...

Group 1 - The core viewpoint of the announcement is that the credit rating for Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.'s convertible bonds remains unchanged at "AA" with a stable outlook [2][3]. - The previous rating for "Jianyou Convertible Bonds" was also "AA" with a stable outlook, indicating consistency in the company's creditworthiness [3]. - The tracking credit rating was conducted by United Credit Rating Co., Ltd., which assessed the company's business, management, and financial situation before issuing the report on June 27, 2025 [3]. Group 2 - The announcement confirms that the company's credit rating and the rating for the convertible bonds have not changed since the last assessment on June 26, 2024 [2][3]. - The report is available for further details on the Shanghai Stock Exchange website [3]. - The announcement was officially made by the board of directors of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. on June 28, 2025 [5].

Group 1 - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., has announced the results of the credit rating for its convertible bonds, maintaining a rating of "AA" for both the bonds and the company itself, with a stable outlook [1][2] - The previous tracking rating for the "Jianyou Convertible Bonds" was conducted on June 26, 2024, with the same ratings of "AA" and a stable outlook [1] - The credit rating agency, United Credit Rating Co., Ltd., performed a comprehensive analysis of the company's business, management, and financial conditions before issuing the 2025 tracking rating report on June 27, 2025 [2]

Core Viewpoint - Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. announces the conditional redemption of its convertible bonds due to the stock price falling below 70% of the conversion price for 30 consecutive trading days, triggering the redemption rights for bondholders [1][3]. Redemption Terms and Price - The conditional redemption clause allows bondholders to sell their convertible bonds back to the company at face value plus accrued interest if the stock price remains below 70% of the conversion price for 30 consecutive trading days during the last two interest years [1][4]. - The redemption price is set at 100.30 RMB per bond, which includes accrued interest and tax [3][5]. - The redemption period is from June 17, 2025, to June 23, 2025, with funds to be disbursed on June 26, 2025 [3][5]. Redemption Process - Bondholders can choose to redeem part or all of their unconverted bonds, and the redemption is not mandatory [4][5]. - The redemption application must be submitted through the Shanghai Stock Exchange trading system during the specified period [4][5]. - If the redemption results in the total face value of the convertible bonds being less than 30 million RMB, the bonds will continue to trade until the end of the redemption period [5]. Interest Calculation - The accrued interest is calculated using the formula: IA = B × i × t / 365, where B is the total face value of the bonds held, i is the annual coupon rate, and t is the number of days since the last interest payment [2][4]. - For the current interest year, the coupon rate is 2.0%, and the interest period is 55 days, resulting in an accrued interest of approximately 0.30 RMB per bond [4].

证券代码：603707 证券简称：健友股份 公告编号：2025-046 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 回售价格：100.30元人民币/张（含当期应计利息、含税） ● 本次满足回售条款而"健友转债"持有人未在上述回售期内申报并实施回售的，计息年度即2025年4月 23日至2026年4月22日不能再行使回售权 ● 证券停复牌情况：适用 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于"健友转债"可选择回售的公告 因回售期间"健友转债"停止转股, 南京健友生化制药股份有限公司（以下简称"本公司"或"公司"）的相 关证券停复牌情况如下： ■ 公司的股票自2025年4月23日至2025年6月9日连续三十个交易日的收盘价格低于本公司可转换公司债券 （以下简称"健友转债"）当期转股价格的70%，且"健友转债"处于最后两个计息年度。根据《南京健友 生化制药股份有限公司公开发行可转换公司债券募集说明书》（以下简称《募集说明书》）的约 定，"健友转债"的有条件回售条款生效。 现依 ...

Core Points - The company announced a cash dividend distribution of 0.1 yuan per share for the fiscal year 2024, totaling approximately 161.56 million yuan [2][4] - The dividend distribution plan was approved at the company's annual general meeting on May 20, 2025 [2][6] - The cash dividends will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [3] Dividend Distribution Details - The total share capital before the distribution is 1,615,634,969 shares, with a cash dividend of 0.1 yuan per share [4] - Shareholders who have completed designated trading can receive their cash dividends on the distribution date at their designated securities firms [5] - For shareholders holding unrestricted circulating shares, the cash dividend will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [5] Taxation Information - For individual shareholders holding unrestricted circulating shares for more than one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of 0.1 yuan per share [8] - For shares held for one year or less, the company will not withhold personal income tax at the time of distribution, but tax will be calculated based on the holding period when the shares are sold [8] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.09 yuan per share [10] Convertible Bond Adjustment - The company announced an adjustment to the conversion price of its convertible bonds, "Jianyou Convertible Bonds," effective June 5, 2025, changing from 24.44 yuan to 24.34 yuan per share [14][16] - The adjustment is based on the company's 2024 annual profit distribution plan, which includes a cash dividend distribution [15][16] - The conversion of the bonds will be suspended from May 28 to June 4, 2025, and will resume on June 5, 2025 [16]

一、可转债基本情况 股票代码：603707 股票简称：健友股份 公告编号：2025-040 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司关于不向下修正"健友转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 截至2025年5月23日，南京健友生化制药股份有限公司（以下简称"公司"）股票在任意连续三十个交 易日中已有十五个交易日的收盘价低于当期转股价格的90%，触发"健友转债"转股价格向下修正条款。 ● 经公司第五届董事会第十三次会议审议，公司董事会决定本次不向下修正转股价格，同时在未来6个 月内（即2025年5月24日至2025年11月23日），如再次触发"健友转债"转股价格向下修正条款的，亦不 提出向下修正方案。在此期间之后（从2025年11月24日起计算），若再次触发"健友转债"转股价格向下 修正条款，届时公司董事会将再次召开会议决定是否行使"健友转债"转股价格的向下修正权利。 7、公司于2023年7月7日起公司因实施2022年年度利润分配方案，"健友 ...

Group 1 - The company will suspend the conversion of its convertible bonds, "Jianyou Convertible Bonds," from May 28, 2025, until the equity distribution registration date due to the implementation of the 2024 annual profit distribution [1][2][3] - The profit distribution plan approved by the shareholders' meeting includes a cash dividend of 1.00 yuan (including tax) for every 10 shares held, based on the total share capital registered on the equity distribution registration date [1][2] - The company will adjust the conversion price of the "Jianyou Convertible Bonds" in accordance with the terms outlined in the bond issuance prospectus following the equity distribution [2][3] Group 2 - The company will publish the relevant equity distribution implementation announcement and the convertible bond conversion price adjustment announcement on May 29, 2025 [2] - Holders of "Jianyou Convertible Bonds" must convert their bonds before May 27, 2025, to enjoy the equity distribution [3] - For detailed information regarding the "Jianyou Convertible Bonds," investors are directed to the bond issuance prospectus published on May 20, 2020 [3]